Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Hellmann

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 29, 2021
Insights from prospective multi-omic profiling of lymphocytes in resected lung cancerA Chow, M D Hellmann
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
'Genotype/immunotype' correlations in resected NSCLCP K Paik, M D Hellmann
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2016
Chemotherapy remains an essential element of personalized care for persons with lung cancersM D Hellmann, B T Li, J E Chaft, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2019
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancerS Peters, M Reck, E F Smit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2021
Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumabB G Topp, K Thiagarajan, D P De Alwis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testingH A Yu, M E Arcila, M D Hellmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2020
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"D Planchard, S Popat, K Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2019
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinibA J Schoenfeld, K C Arbour, H Rizvi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2018
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upD Planchard, S Popat, K Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2020
Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitorsN Shaverdian, J Beattie, M Thor, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 29, 2021
Insights from prospective multi-omic profiling of lymphocytes in resected lung cancerA Chow, M D Hellmann
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
'Genotype/immunotype' correlations in resected NSCLCP K Paik, M D Hellmann
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2016
Chemotherapy remains an essential element of personalized care for persons with lung cancersM D Hellmann, B T Li, J E Chaft, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2019
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancerS Peters, M Reck, E F Smit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2021
Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumabB G Topp, K Thiagarajan, D P De Alwis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testingH A Yu, M E Arcila, M D Hellmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2020
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"D Planchard, S Popat, K Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2019
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinibA J Schoenfeld, K C Arbour, H Rizvi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2018
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upD Planchard, S Popat, K Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2020
Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitorsN Shaverdian, J Beattie, M Thor, et al.
Pageof 3